Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Cancer

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2016.05.017PMID 27323348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

  2015cited by this paper
• Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

  2010influential reference
• Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.

  2009cited by this paper
• Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.

  2008cited by this paper
• Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.

  2007cited by this paper
• Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer.

  2006cited by this paper
• Feasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.

  2004cited by this paper
• Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.

  2003cited by this paper
• Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study.

  2003cited by this paper
• Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study.

  2002cited by this paper
• Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma

  2001cited by this paper
• Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.

  1999cited by this paper
• Neoadjuvant chemotherapy in advanced ovarian cancer.

  1996cited by this paper
• Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer.

  1991cited by this paper

• Minimally invasive surgery for advanced-stage ovarian cancer: a review of evidence and emerging paradigms.

  2026cites this paper
• The Impact of the Number of Neoadjuvant Chemotherapy Cycles on Outcomes in Advanced Ovarian Cancer: A Narrative Review.

  2026cites this paper
• Incidence and impact on survival outcomes of postoperative radiological evidence of residual disease in women with advanced stage ovarian cancer undergoing debulking surgery: a meta-analysis.

  2026cites this paper
• ТРЕПАН-БІОПСІЯ ПІД УЛЬТРАЗВУКОВИМ НАВЕДЕННЯМ ЯК МЕТОД ГІСТОЛОГІЧНОЇ ВЕРИФІКАЦІЇ ПРИ РАКУ ЯЄЧНИКА

  2026cites this paper
• Predictive value of the KELIM in neoadjuvant treatment for patients with advanced ovarian cancer

  2026cites this paper
• Minimally invasive interval debulking surgery in advanced ovarian cancer: a real-life PICture of pAtientS’ SelectiOn

  2026cites this paper
• Neoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery for Metastatic Endometrial Cancer

  2026cites this paper
• Evaluation of total retroperitoneal en-bloc resection of multivisceral-peritoneal packet (TROMP) in advanced ovarian cancer: A single-center cohort study.

  2025cites this paper
• Cáncer epitelial de ovario en estadios IIIC y IV: cirugía citorreductora primaria versus cirugía citorreductora de intervalo

  2025cites this paper
• Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer.

  2025cites this paper
• Enhancing Prognosis in Advanced Ovarian Cancer: Primary Cytoreductive Surgery and Adjuvant Chemotherapy or Neoadjuvant Chemotherapy and Interval Cytoreduction—A Single-Center Retrospective Observational Study

  2025cites this paper
• Survival after interval and delayed cytoreduction surgery in advanced ovarian cancer: a Global Gynaecological Oncology Surgical Outcomes Collaborative-Led Study (GO SOAR2).

  2025cites this paper
• COMPARISON OF ULTRASOUND-GUIDED TRUCUT NEEDLE BIOPSY AND LAPAROSCOPY IN THE DIAGNOSIS OF HIGH-GRADE SEROUS OVARIAN CANCER

  2025cites this paper
• Optimal timing of primary debulking surgery in advanced ovarian cancer: insights from the TRUST trial

  2025cites this paper
• Assessment of textbook oncologic outcome after neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer

  2025cites this paper
• The prognosis impact of NACT-IDS and PDS in advanced ovarian cancer: a systematic review and meta-analysis

  2025cites this paper
• Real-world outcomes of neoadjuvant chemotherapy for advanced ovarian cancer: What happens to patients who never undergo surgery?

  2025cites this paper
• Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer

  2025cites this paper
• Failure of early interval debulking surgery after standard neoadjuvant chemotherapy: May bevacizumab add something? A large retrospective study.

  2025cites this paper
• Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms

  2025cites this paper
• Trends in Surgical Outcomes and Overall Survival Among Women Undergoing Debulking Surgery for Advanced Ovarian Cancer in the U.S: Analysis of the National Cancer Database

  2025influential citation
• Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update

  2025cites this paper
• Ovarian clear cell carcinoma: open questions on the management and treatment algorithm

  2025cites this paper
• Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer.

  2025cites this paper
• Minimally invasive surgery in advanced and recurrent ovarian cancer: current evidence and future directions.

  2025cites this paper
• Neoadjuvant Chemotherapy, Case Volume, and Mortality in Advanced Ovarian Cancer.

  2025cites this paper
• Diagnostic Laparoscopy for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancers: A Retrospective Study

  2025influential citation
• Optimising Chemotherapy for Advanced High-Grade Serous Ovarian Cancer via Delay-Differential Equations

  2025cites this paper
• Implementation of extensive cytoreductive surgery protocol in advanced epithelial ovarian cancer: Real‐world data on surgical treatment distribution and survival of the whole patient cohort; a single center experience

  2025cites this paper
• Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study.

  2025cites this paper
• Surgical Management of Gynecologic Cancers.

  2025cites this paper
• Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis.

  2025cites this paper
• Surgical timing in advanced ovarian cancer during the TRUST trial era: A systematic review, meta-analysis and study-level meta-regression of randomized controlled trials.

  2025cites this paper
• Correlation between preoperative PCI imaging, intraoperative PCI measurement, and overall survival in peritoneal carcinomatosis secondary to ovarian, tubal, and primary peritoneal carcinoma

  2025cites this paper
• Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resection

  2024cites this paper
• Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer

  2024cites this paper
• Intraoperative Normothermic Intraperitoneal Chemotherapy Following Optimal Cytoreduction in Advanced Ca Ovary: A Feasibility Study

  2024cites this paper
• Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer

  2024cites this paper
• CORE-NEEDLE BIOPSY UNDER ULTRASOUND GUIDANCE AS A METHOD OF HISTOLOGICAL VERIFICATION IN MALIGNANT OVARIAN NEOPLASMS

  2024cites this paper
• Tubal Cancer Clinical Management: Two Exceptional Scenarios and a Review of the Literature

  2024cites this paper
• British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024.

  2024cites this paper
• A Review of the Status of Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer

  2024cites this paper
• Drug Therapy and Progress in Advanced Epithelial Ovarian Cancer

  2024cites this paper
• Primary vs. interval cytoreduction for high-grade serous ovarian cancer: oncological outcomes from a retrospective study at a single tertiary referral center

  2024cites this paper
• Does neoadjuvant chemotherapy reduce surgical complexity in patients with advanced-stage epithelial ovarian cancer?

  2024cites this paper
• Potential Risks of Severe Infection Following the Exploratory Laparoscopy for Advanced Ovarian Cancer: A Case Report and a Literature Review

  2024cites this paper
• Effect of initial treatment with chemotherapy or surgery on wound complications in patients with advanced ovarian cancer: A meta‐analysis

  2024cites this paper
• Survival outcomes of epithelial ovarian cancer treated at a tertiary-level hospital in India.

  2024cites this paper
• Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.

  2024cites this paper
• Association of Chemotherapy Response Score with Multidrug Resistance 1 and CA125 ELIMination Rate Constant K in Patients with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.

  2024cites this paper
• PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China

  2024cites this paper
• Synoptic Reporting for Pretreatment CT Examinations in Patients With Advanced Ovarian Cancer: Impact on Documentation of Disease Sites and Physician Satisfaction.

  2023cites this paper
• A retrospective analysis for investigating the relationship between FIGO stage IVA/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer

  2023cites this paper
• Predicting Neoadjuvant Chemotherapy Response and High-Grade Serous Ovarian Cancer From CT Images in Ovarian Cancer with Multitask Deep Learning: A Multicenter Study.

  2023cites this paper
• Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study

  2023cites this paper
• Approaches to therapy for ovarian cancer yesterday, today, tomorrow

  2023cites this paper
• Calculating surgical readmission rates in gynecologic oncology: The impact of patient factors.

  2023cites this paper
• Progress in Clinical Research of NACT-IDS in Advanced Epithelial Ovarian Cancer

  2023cites this paper
• Prognostic impact of cytoreductive surgery conducted with primary intent, versus cytoreductive surgery after neoadjuvant chemotherapy, in the management of patients with advanced epithelial ovarian cancers: a multicentre, propensity score‐matched study from the FRANCOGYN group

  2023cites this paper
• Cytoreductive Surgery with HIPEC as Primary Treatment for Advanced Epithelial Ovarian Carcinoma: Upfront or Interval—ISPSM Collaborative Study

  2023cites this paper
• Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion coefficient values in patients with ovarian cancer

  2023cites this paper
• Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer

  2023cites this paper
• Critical Analysis of Advanced High-Grade Serous Epithelial Ovarian Cancer in Women: An Experience of 100 Cases from a Regional Cancer Center in Northeast India

  2023cites this paper
• Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.

  2023cites this paper
• Mass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective

  2023cites this paper
• The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients

  2023cites this paper
• Beyond post-operative readmissions: analysis of the impact of unplanned readmissions during primary treatment of advanced-stage epithelial ovarian cancer on long-term oncology outcome

  2023cites this paper
• Habitat Radiomics Based on MRI for Predicting Platinum Resistance in Patients with High-Grade Serous Ovarian Carcinoma: A Multicenter Study.

  2023cites this paper
• Cytoreductive surgery in patients with advanced ovarian cancer: Surgical complexity score and postoperative complications

  2023cites this paper
• A retrospective study of Pipelle endometrial biopsy for ovarian, fallopian tube, and peritoneal cancers

  2023cites this paper
• Characteristics, Treatment Patterns and Survival of International Federation of Gynecology and Obstetrics Stage IV Epithelial Ovarian Cancer—A Population-Based Study

  2023cites this paper
• The Cukurova score in the prediction of primary cytoreduction in ovarian cancer

  2023cites this paper
• Current status of vulvar cancer in Japan: analysis of the Japanese Gynecologic Oncology Group nationwide survey study.

  2023cites this paper
• Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis

  2023cites this paper
• Role of Neoadjuvant Chemotherapy on Advanced Epithelial Ovarian Cancer

  2023cites this paper
• Resistance prediction in high‐grade serous ovarian carcinoma with neoadjuvant chemotherapy using data‐independent acquisition proteomics and an ovary‐specific spectral library

  2023cites this paper
• Four patients with advanced ovarian cancer who underwent diagnostic laparoscopic surgery

  2023cites this paper
• Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study

  2022cites this paper
• Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline

  2022cites this paper
• The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery

  2022cites this paper
• Effect of neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval tumor cell reduction on the prognosis of advanced epithelial ovarian cancer

  2022cites this paper
• Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis

  2022cites this paper
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20 years’ experience

  2022cites this paper
• CASE REPORT A multidisciplinary approach for complete cytoreduction after neoadjuvant chemotherapy in advanced-stage ovarian cancer: a case report

  2022cites this paper
• Efficacy and Safety of Minimally Invasive Surgery Versus Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A Systematic Review and A Meta-Analysis

  2022cites this paper
• Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges

  2022cites this paper
• Review of neoadjuvant chemotherapy characteristics in advanced epithelial ovarian cancer: experience from two cancer centers

  2022cites this paper
• 18F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study

  2022cites this paper
• Relationship Between Neoadjuvant Chemotherapy and Log Odds of Positive Lymph Nodes and Their Prognostic Role in Advanced Ovarian Cancer Patients With Optimal Cytoreductive Surgery

  2022cites this paper
• Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer.

  2022cites this paper
• CT of Ovarian Cancer for Primary Treatment Planning: What the Surgeon Needs to Know-Radiology In Training.

  2022cites this paper
• Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis

  2022influential citation
• Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction

  2022cites this paper
• The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review

  2021cites this paper
• Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.

  2021cites this paper
• Neoadjuvant Chemotherapy Followed by Surgery versus Primary Surgery in Advanced Epithelial Ovarian Cancer: A Review of Outcomes at National Institute of Cancer Research Hospital in Bangladesh

  2021cites this paper
• Recommendations on the pharmacological treatment of epithelial ovarian cancer in Mexico.

  2021cites this paper
• Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review

  2021cites this paper
• Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study

  2021influential citation
• Interval debulking surgery for advanced ovarian cancer: when, how and why?

  2021cites this paper